DigiLum™ – Reinvigorating Proven Therapy
Revolutionary New Administration of PDT
Our DigiLum™ solution effectively addresses positive surgical margins, offering an alternative to intraoperative radiotherapy and chemotherapy. By leveraging Gleolan™’s dual diagnostic and therapeutic capabilities, we enhance real-time visualization of positive margins after tumor resection, allowing for targeted photodynamic therapy (PDT) to eliminate residual cancer cells.
Positive surgical margins are especially challenging in advanced-stage tumors, which increase the risk of recurrence. With minimal off-target effects and Gleolan™’s high selectivity, our method is specifically designed to address this issue. A Phase I/II clinical study is currently recruiting participants to evaluate the safety and initial efficacy of this approach in improving local tumor control in patients with locally advanced colorectal cancer.
3-Step Enhanced Visualization and Local Control
A light applicator inserted in patient
Applicator positioned, secured
Touchscreen start, automated light delivery
Unlocking the Power of PDT with the Revolutionary DigiLum™ System for Enhanced Cancer Treatment
Discover how our innovative DigiLum™ system is transforming the landscape of Photodynamic Therapy (PDT) by expanding its application to various cancer sites and intraoperative surgical settings. This groundbreaking system allows us to deliver a proven therapy to a larger patient population, ensuring comprehensive treatment options.
The Benefits of PDT: Mechanism of Action and Clinical Outcomes
PDT operates through a unique mechanism of action that induces oxidative stress without toxic side effects. This advanced approach enables a range of clinical outcomes, including effective tumor ablation, immunogenic cell death, and local tumor control for patients undergoing surgical resection. Unlike traditional therapies, PDT is tumor-agnostic, showing no signs of acquired resistance. It works seamlessly with other treatments, ensuring minimal damage to healthy tissue for optimal cosmetic and organ function preservation.
At OncoLux, we are at the forefront of pioneering new indications for PDT as a more tolerable, effective, and toxicity-free alternative to chemotherapy and radiotherapy.
Local Treatment with a Systemic Response: Enhancing Immunotherapy Efficacy
Our initial focus for the DigiLum™ system highlights the application of PDT as an immune adjuvant therapy, specifically designed to enhance the response rates of patients suffering from advanced lung cancer who are receiving standard immune checkpoint blockade therapies. Our targeted approach selectively destroys local tumor cells while simultaneously empowering the immune system to identify and eradicate both residual and distant cancerous cells.
In contrast to other immunogenic cell death methods, such as chemotherapy and radiotherapy, which can be indiscriminate and immunosuppressive, our PDT strategy preserves essential immune components, eliminating toxic side effects and severe reactions.
Advancing PDT for Lung Cancer and Pleural Disease
Our mission at OncoLux is clear: to refine and promote PDT as a more effective and tolerable treatment option, particularly when combined with immunotherapy for patients battling lung cancer and pleural disease. Join us in revolutionizing cancer treatment through the power of innovative PDT strategies with the DigiLum™ system.
